Page last updated: 2024-12-06

3-fluoropyruvate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Fluoropyruvate (3FP) is a synthetic analog of pyruvate, a key intermediate in cellular metabolism. It is generated through fluorination of pyruvate. 3FP is a potent inhibitor of various metabolic enzymes, including pyruvate kinase and lactate dehydrogenase, disrupting glycolysis and cellular energy production. Its inhibitory effects on these enzymes make it a promising target for cancer therapy, as cancer cells often rely heavily on glycolysis for their survival. Furthermore, 3FP has been shown to induce apoptosis and inhibit tumor growth in preclinical models. It is also being studied as a potential therapeutic agent for other conditions, such as diabetes and neurodegenerative diseases. Research into 3FP focuses on its therapeutic potential, its mechanisms of action, and its effects on different cell types and tissues. '

3-fluoropyruvate: a substrate for E coli pyruvate dehydrogenase; structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-fluoropyruvic acid : A pyruvic acid derivative having a 3-fluoro substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-fluoropyruvate : The anion of 3-fluoropyruvic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID67946
CHEMBL ID1162543
CHEBI ID55521
SCHEMBL ID61445
MeSH IDM0068007

Synonyms (28)

Synonym
chebi:55521 ,
3-fluoropyruvic acid
pyruvic acid, 3-fluoro-
nsc 21734
brn 1746780
3-fluoro-2-oxopropanoic acid
3-fluoropyruvate
propanoic acid, 3-fluoro-2-oxo-
433-48-7
nsc21734
fluoropyruvic acid
pyruvic acid, 3-fluoro
nsc-21734
wln: qnu1v1f
fluoropyruvate
.omega.-fluoropyruvic acid
pyruvic acid, fluoro-
beta-fluoropyruvic acid
AKOS006377022
CHEMBL1162543
040om3qf5r ,
unii-040om3qf5r
BRD-K01779529-236-01-5
SCHEMBL61445
mfcd01686785
65S ,
Q27124338
DTXSID30962985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
diaminopimelate biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lysine biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lysine biosynthetic process via diaminopimelate4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
diaminopimelate biosynthetic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
small molecule metabolic process4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
4-hydroxy-tetrahydrodipicolinate synthase activity4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
lyase activity4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
identical protein binding4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasm4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
cytosol4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
cytosol4-hydroxy-tetrahydrodipicolinate synthaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID388791Inhibition of Escherichia coli DHDPS2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Irreversible inhibition of dihydrodipicolinate synthase by 4-oxo-heptenedioic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (33.33)18.7374
1990's6 (25.00)18.2507
2000's2 (8.33)29.6817
2010's7 (29.17)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.71 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]